Insider Selling: Omeros (NASDAQ:OMER) VP Sells $466,250.00 in Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of Omeros stock in a transaction on Friday, August 28th. The stock was sold at an average price of $18.65, for a total transaction of $466,250.00. Following the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,730. This represents a 99.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Omeros Trading Up 1.3%

Shares of Omeros stock opened at $19.11 on Friday. The company has a market capitalization of $1.38 billion, a PE ratio of 14.93 and a beta of 2.60. Omeros Corporation has a 12 month low of $3.94 and a 12 month high of $19.65. The stock’s fifty day simple moving average is $13.31 and its 200 day simple moving average is $12.24.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. Analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on OMER. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.00.

Institutional Trading of Omeros

A number of hedge funds and other institutional investors have recently modified their holdings of OMER. Acadian Asset Management LLC acquired a new position in Omeros during the first quarter valued at approximately $357,000. XTX Topco Ltd acquired a new position in shares of Omeros during the 2nd quarter worth approximately $191,000. Invesco Ltd. raised its stake in shares of Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 29,644 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after purchasing an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Omeros in the 2nd quarter valued at approximately $40,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.